Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults.

Chen, Guiling; Li, Nan; Dai, Xiahong; Tu, Shiyan; Shen, Zhenwei; Wu, Kaiqi; Jin, Tinghan; Wu, Jiajun; Peng, Conggao; Sheng, Guoping; Zhu, Mengfei; Tang, Lingling; Li, Lanjuan

Chen, Guiling; Li, Nan; Dai, Xiahong; Tu, Shiyan; Shen, Zhenwei; Wu, Kaiqi; Jin, Tinghan; Wu, Jiajun; Peng, Conggao; Sheng, Guoping; Zhu, Mengfei; Tang, Lingling; Li, Lanjuan.

Afiliação

Chen G; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Li N; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Dai X; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Tu S; The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
Shen Z; Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Wu K; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Jin T; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Wu J; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Peng C; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China.
Sheng G; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China. guoping.sheng@shulan.com.
Zhu M; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China. mengfei.zhu@shulan.com.
Tang L; Phase I Clinical Trial Unit, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Dongxin Road, 848, Hangzhou, 310000, China. lingling.tang@shulan.com.
Li L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310

Infect Dis Ther ; 12(2): 663-675, 2023 Feb.

Article em En | MEDLINE | ID: mdl-36697937

Palavras-chave

C5a; Clinical trial; Complement system; Phase 1; Severe COVID-19

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Infect Dis Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Nova Zelândia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google